Effects of Supplemental Vitamin D and Calcium on Biomarkers of Inflammation in Colorectal Adenoma Patients: A Randomized, Controlled Clinical Trial
- 1 October 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 4 (10) , 1645-1654
Abstract
Vitamin D and calcium affect several pathways involved in inflammation, tumor growth, and immune surveillance relevant to carcinogenesis. Also, epidemiologic evidence indicates that calcium and vitamin D may reduce risk for developing colorectal adenomas and cancer. To investigate the effects of calcium and vitamin D on biomarkers of inflammation in colorectal adenoma patients, we conducted a pilot, randomized, double-blind, placebo-controlled, 2 × 2 factorial clinical trial (n = 92) of 2 g/d calcium and/or 800 IU/d vitamin D3 supplementation versus placebo over 6 months. Plasma concentrations of proinflammatory markers [C-reactive protein (CRP), TNF-α, interleukin (IL)-6, IL-1β, and IL-8] and an anti-inflammatory marker (IL-10) were measured using ELISAs. After 6 months of treatment, in the vitamin D3 supplementation group, CRP decreased 32% overall (P = 0.11), 37% in men (P = 0.05), and 41% among non–nonsteroidal anti-inflammatory drug (NSAID) users (P = 0.05) relative to placebo. In the vitamin D3 supplementation group, TNF-α decreased 13%, IL-6 32%, IL-1β 50%, and IL-8 15%; in the calcium supplementation group, IL-6 decreased 37%, IL-8 11%, and IL-1β 27%. Although these changes were not statistically significant, a combined inflammatory markers z-score decreased 77% (P = 0.003) in the vitamin D3 treatment group overall, 83% (P = 0.01) among men, and 48% among non-NSAID users (P = 0.01). There was no evidence of synergy between vitamin D3 and calcium or effects on IL-10. These preliminary results are consistent with a pattern of reduction in tumor-promoting inflammation biomarkers with vitamin D3 or calcium supplementation alone and support further investigation of vitamin D3 as a chemopreventive agent against inflammation and colorectal neoplasms. Cancer Prev Res; 4(10); 1645–54. ©2011 AACR.Keywords
This publication has 51 references indexed in Scilit:
- Effects of Supplemental Vitamin D and Calcium on Oxidative DNA Damage Marker in Normal Colorectal Mucosa: A Randomized Clinical TrialCancer Epidemiology, Biomarkers & Prevention, 2010
- Effects of Vitamin D and Calcium on Proliferation and Differentiation In Normal Colon Mucosa: a Randomized Clinical TrialCancer Epidemiology, Biomarkers & Prevention, 2009
- The NF-κB/AKT-dependent Induction of Wnt Signaling in Colon Cancer Cells by Macrophages and IL-1βCancer Microenvironment, 2009
- Effects of Vitamin D and Calcium Supplementation on Markers of Apoptosis in Normal Colon Mucosa: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialCancer Prevention Research, 2009
- Systematic review of the association between circulating interleukin-6 (IL-6) and cancerEuropean Journal of Cancer, 2008
- Circulating Levels of Inflammatory Cytokines and Risk of Colorectal AdenomasCancer Research, 2008
- Vitamin D signalling pathways in cancer: potential for anticancer therapeuticsNature Reviews Cancer, 2007
- The cyclooxygenase‐2‐mediated prostaglandin signaling is causally related to epithelial carcinogenesisMolecular Carcinogenesis, 2007
- Vitamin D receptor-mediated suppression of RelB in antigen presenting cells: A paradigm for ligand-augmented negative transcriptional regulationArchives of Biochemistry and Biophysics, 2007
- Noncalcemic Actions of Vitamin D Receptor LigandsEndocrine Reviews, 2005